Klinikum der J. W. Goethe-Universität, Medizinische Klinik 1, Theodor-Stern-Kai 7, Frankfurt am Main, Germany.
Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S323-31. doi: 10.1016/j.dld.2013.07.007.
The introduction of telaprevir and boceprevir in the treatment of chronically HCV genotype 1 infected patients has led to substantially improved sustained virologic response rates and shorter treatment duration for a growing group of patients. Management and monitoring of patients receiving protease inhibitor-based triple therapy is of major importance and has become more complicated. Close monitoring of HCV RNA levels for patients on protease inhibitor-based therapy to identify subjects who are eligible for shortening of treatment duration, are virological non-responders or are in danger of experiencing a viral breakthrough is strongly recommended. Several virological tools including qualitative and quantitative HCV RNA assays for detection and quantification of HCV RNA are commercially available. We review these methods and their implications for HCV therapy as well as current sustained virologic response definition, stopping rules and recommendations for protease inhibitor-based treatment durations.
替拉瑞韦和博赛匹韦的引入使得慢性 HCV 基因型 1 感染患者的持续病毒学应答率得到了显著提高，治疗时间也有所缩短。对于越来越多的患者来说，接受蛋白酶抑制剂三联疗法的管理和监测变得非常重要，也变得更加复杂。强烈建议对接受蛋白酶抑制剂治疗的患者进行 HCV RNA 水平的密切监测，以确定那些有资格缩短治疗时间、病毒学无应答或有发生病毒突破风险的患者。有几种病毒学检测工具，包括定性和定量 HCV RNA 检测方法，可用于 HCV RNA 的检测和定量。我们将对这些方法及其对 HCV 治疗的意义，以及目前的持续病毒学应答定义、停药标准和基于蛋白酶抑制剂的治疗持续时间的建议进行综述。
